FDA cleared Priovant’s Lisraya (brepocitinib) for dermatomyositis, marking the first approval for a Roivant subsidiary drug licensed from Pfizer and expanding the company’s rare-inflammation portfolio. The once-daily pill is positioned against a standard of high-dose steroids and other immunosuppressants. Separately, FDA also cleared Adicet Bio’s IND for ADI-212 in metastatic castration-resistant prostate cancer, enabling advancement of the program into clinical testing. Together, the moves highlight ongoing acceleration in rare and difficult-to-treat indications, with developers using regulatory clearance to extend clinical momentum.